Publications

  1. Zhu M, Sonbol MB, Bassam Sonbol M, Halfdanarson T, Hobday T, Ahn D, Ma WW, Bekaii-Saab T. Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Oncologist. 2020 Jun 8 Epub 2020 June 08
    View PubMed
  2. Almquist DR, Ahn DH, Bekaii-Saab TS. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. BioDrugs. 2020 Jun; 34 (3):349-362
    View PubMed
  3. Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2020 May; 25 (5):380-e763 Epub 2019 Dec 11
    View PubMed
  4. Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020 Mar 1; 6 (3):e194489 Epub 2020 Mar 12
    View PubMed
  5. Ahn DH, Bekaii-Saab T. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. Chin Clin Oncol. 2020 Feb; 9 (1):6 Epub 2020 Feb 20
    View PubMed
  6. Barzi A, Miksad R, Surinach A, Corvino FA, Wang S, Torres AZ, Mamlouk K, Pulgar S, Valderrama A, Bekaii-Saab T, Ahn D. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas. 2020 Feb; 49 (2):193-200
    View PubMed
  7. Ahn DH, Bekaii-Saab T. AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time? Chin Clin Oncol 2019 Oct; 8 (S1):S19 Epub 2019 May 06
    View PubMed
  8. Sonbol MB, Benkhadra R, Wang Z, Firwana B, Walden DJ, Mody K, Hubbard JM, Murad MH, Ahn DH, Bekaii-Saab T. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. Oncologist. 2019 Sep; 24 (9):1174-1179 Epub 2019 June 04
    View PubMed
  9. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Aug; 20 (8):1070-1082 Epub 2019 June 28
    View PubMed
  10. Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Jun 15; 25 (12):3495-3507 Epub 2019 Feb 25
    View PubMed
  11. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1; 5 (6):824-830
    View PubMed
  12. Arsanjani R, Agasthi P, Ahn DH, Mookadam F, Yang M. Metastatic Neuroendocrine Tumor with Cardiac Involvement Utilizing Multi-Modality Imaging. Korean Circ J. 2019 Jun; 49 (6):557-558 Epub 2019 Apr 04
    View PubMed
  13. Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, Reni M, Li CP, O'Neil B, Van Cutsem E, Bekaii-Saab T. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncol. 2019 Apr; 15 (12):1295-1302 Epub 2019 Feb 15
    View PubMed
  14. Sonbol MB, Ahn DH, Bekaii-Saab T. Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. Biomedicines. 2019 Mar 10; 7 (1)
    View PubMed
  15. Ahn DH, Bekaii-Saab T. Watch and Wait in Rectal Cancer: Who's In and Who's Out? J Oncol Pract 2019 Mar; 15 (3):133-134
    View PubMed
  16. Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 2019 Jan; 19 (1):80-87 Epub 2018 Nov 10
    View PubMed
  17. Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018 Dec; 36 (6):1037-1043 Epub 2018 May 22
    View PubMed
  18. Ahn D, Barzi A, Miksad RA, Surinach A, Corvino FA, Valderrama A, Mamlouk K, Pulgar S, Bekaii-Saab T. Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics. Ann Oncol. 2018 Oct; 29 Suppl 8:viii251
    View PubMed
  19. Weidner TK, Kidwell JT, Glasgow AE, Menias CO, Ahn DH, Pai RK, Heigh RI, Mishra N. Small Intestine Neuroendocrine Tumor in a Patient With MUTYH Adenomatous Polyposis-Case Report and SEER Analysis. Clin Colorectal Cancer. 2018 Sep; 17 (3):e545-e548 Epub 2018 May 09
    View PubMed
  20. DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy. 2018 Sep; 10 (12):1077-1091
    View PubMed
  21. Ahn DH, Ramanathan RK, Bekaii-Saab T. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers (Basel). 2018 Jun 11; 10 (6) Epub 2018 June 11
    View PubMed
  22. Meric-Bernstam F, Arkenau H, Tran B, Bahleda R, Kelley R, Hierro C, Ahn D, Zhu A, Javle M, Winkler R, He H, Huang J, Goyal L. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann Oncol. 2018 Jun; 29 Suppl 5:v100 Epub 2020 Jan 07
    View PubMed
  23. Bekaii-Saab T, Ou F, Anderson D, Ahn D, Boland P, Ciombor K, Jacobs N, Desnoyers R, Cleary J, Meyers J, Chiorean E, Pedersen K, Barzi A, Sloan J, McCune J, Lacouture M, Lenz H, Grothey A. Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Ann Oncol. 2018 Jun; 29 Suppl 5:v105 Epub 2020 Jan 07
    View PubMed
  24. Ahn DH, Reardon J, Ahn CW, Bupathi M, Mikhail S, Wu CS, Bekaii-Saab T. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Int J Cancer. 2018 Apr 15; 142 (8):1671-1675 Epub 2017 Nov 17
    View PubMed
  25. Ahn DH, Bekaii-Saab TS. Genetic Diversity and Treatment Implications in Gastric and Gastroesophageal Cancers: One Size Does Not Fit All. J Oncol Pract 2018 Apr; 14 (4):227-228
    View PubMed
  26. DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncol. 2018 Mar; 14 (6):553-566 Epub 2018 Feb 20
    View PubMed
  27. Bogenberger JM, DeLeon TT, Arora M, Ahn DH, Borad MJ. Emerging role of precision medicine in biliary tract cancers. NPJ Precis Oncol. 2018; 2:21 Epub 2018 Oct 03
    View PubMed
  28. Ahn DH, Ramanathan RK. Targeting the stroma in pancreatic cancer. Chin Clin Oncol. 2017 Dec; 6 (6):65
    View PubMed
  29. Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer. 2017 Dec 1; 123 (23):4680-4686 Epub 2017 Aug 17
    View PubMed
  30. Ahn DH, Grothey A. Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. Lancet Oncol 2017 Nov; 18 (11):1427-1428 Epub 2017 Sept 25
    View PubMed
  31. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 Jul; 22 (7):804-810 Epub 2017 May 09
    View PubMed
  32. Ahn DH, Bekaii-Saab T. Response to Drs Von Hoff and Renschler. Ther Adv Med Oncol. 2017 Jun; 9 (6):445-446 Epub 2017 May 30
    View PubMed
  33. Yang J, Farren MR, Ahn D, Bekaii-Saab T, Lesinski GB. Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opin Ther Targets. 2017 May; 21 (5):485-498 Epub 2017 Mar 17
    View PubMed
  34. Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol. 2017 Apr; 8 (2):293-301
    View PubMed
  35. Bupathi M, Ahn DH, Bekaii-Saab T. Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017 Apr; 6 (2):91-100
    View PubMed
  36. Ahn DH, Bekaii-Saab T. The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. Biomedicines. 2017 Mar 4; 5 (1) Epub 2017 Mar 04
    View PubMed
  37. Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S, Bekaii-Saab T. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol. 2017 Feb; 9 (2):75-82 Epub 2016 Nov 02
    View PubMed
  38. Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ. Oncolytic virotherapy in upper gastrointestinal tract cancers. Oncolytic Virother. 2017; 7:13-24 Epub 2018 Mar 23
    View PubMed
  39. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122 (24):3838-3847 Epub 2016 Sept 13
    View PubMed
  40. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 Dec 1; 122 (23):3657-3666 Epub 2016 Aug 06
    View PubMed
  41. Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol. 2016 Jul 7; 22 (25):5668-77
    View PubMed
  42. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24: (6)1150-8.
    View PubMed
  43. Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naive Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2016 May 15; 22: (10)2565-74.
    View PubMed
  44. Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, Bekaii-Saab T. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Med Oncol. 2016 Apr; 33: (4)37.
    View PubMed
  45. Ahn DH, Ozer HG, Hancioglu B, Lesinski GB, Timmers C, Bekaii-Saab T. Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. Oncotarget. 2016 Feb 02; 7: (5)5306-12.
    View PubMed
  46. Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncol. 2016 Feb; 12: (4)525-31.
    View PubMed
  47. Ahn DH, Bekaii-Saab T. Adjuvant chemotherapy for rectal cancer after neoadjuvant treatment: FOLFOX, 5-FU, or observation Current Colorectal Cancer Reports. 2016; 12: (5)260-5.
  48. Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer. 2016; 6:21-30.
    View PubMed
  49. Ahn DH, Williams TM, Goldstein DA, El-Rayes B, Bekaii-Saab T. Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev. 2016 Jan; 42: 10-7.
    View PubMed
  50. Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Sci Rep. 2015 Jul 10; 5:12122.
    View PubMed
  51. Malhotra L, Ahn D, Bloomston M. The Pathogenesis, Diagnosis, and Management of Pancreatic Cancer J Gastrointest Dig Syst .2015;5:278.
  52. Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T. The Efficacy of Adjuvant Chemotherapy in Patients With Stage IIIII Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2015 Feb 25;
    View PubMed
  53. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; e222-7.
    View PubMed
  54. Ahn DH, Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 2014; 112-5.
    View PubMed
  55. Ahn DH, Mehta N, Yorio JT, Xie Y, Yan J, Gerber DE. Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer. Clin Lung Cancer. 2013 Nov; 14: (6)644-50.
    View PubMed
  56. Gerber DE, Dahlberg SE, Sandler AB, Ahn D, Schiller JH, Brahmer JR, Johnson DH. Baseline tumour measurements predict survival in advanced non-small cell lung cancer. Br J Cancer. 2013 Sep 17; 109: (6)1476-81.
    View PubMed
  57. Ahn DH, Illum HB, Wang DH, Sharma A, Dowell JE. Upper extremity venous thrombosis in patients with cancer with peripherally inserted central venous catheters: a retrospective analysis of risk factors. J Oncol Pract. 2013 Jan; 9: (1)e8-12.
    View PubMed
  58. Ahn D, Brickner ME, Dowell J. Embolic stroke secondary to an indwelling catheter in a patient with a patent foramen ovale: a case report and review of the literature. Clin Adv Hematol Oncol. 2012 May; 10: (5)335-7.
    View PubMed
  59. Guturu P, Sagi SV, Ahn D, Jaganmohan S, Kuo YF, Sood GK. Capsule endoscopy with PILLCAM ESO for detecting esophageal varices: a meta-analysis. Minerva Gastroenterol Dietol. 2011 Mar; 57: (1)1-11.
    View PubMed
  60. Ahn D, Guturu P. Meta-analysis of capsule endoscopy in patients diagnosed or suspected with esophageal varices. World J Gastroenterol. 2010 Feb 14; 16: (6)785-6.
    View PubMed
  61. Ahn C, Ahn D. Randomized clinical trials in stroke research. J Investig Med. 2010 Feb; 58: (2)277-81.
    View PubMed
  62. Ahn C, Hu F, Skinner CS, Ahn D. Effect of imbalance and intracluster correlation coefficient in cluster randomization trials with binary outcomes when the available number of clusters is fixed in advance. Contemp Clin Trials. 2009 Jul; 30: (4)317-20.
    View PubMed